Profil
Jean Jacques Mention is currently the Chief Business Officer at OSE Immunotherapeutics SA. Prior to this, he held positions as Director of Business Development at Axenis SAS and Head of Business Development at genOway SA.
Postes actifs de Jean Jacques Mention
| Sociétés | Poste | Début |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Corporate Officer/Principal | - |
Anciens postes connus de Jean Jacques Mention
| Sociétés | Poste | Fin |
|---|---|---|
| GENOWAY | Corporate Officer/Principal | - |
Axenis SAS
 Axenis SAS BiotechnologyHealth Technology Part of genOway SA, Axenis SAS develops gene technology and products. The company is based in Paris, France. Axenis was acquired by genOway SA on September 04, 2018 for $0.23 million. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| GENOWAY | Health Technology |
| Entreprise privées | 1 |
|---|---|
Axenis SAS
Axenis SAS BiotechnologyHealth Technology Part of genOway SA, Axenis SAS develops gene technology and products. The company is based in Paris, France. Axenis was acquired by genOway SA on September 04, 2018 for $0.23 million. | Health Technology |